Laflunimus

Products

Inquiry

Cat. No.: IBDI-436262

Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor.

Size (Solution): 10 mM * 1 mL in DMSO

Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution

Size (Solid):

Product Details

Target	Dihydroorotate Dehydrogenase \| DNA/RNA Synthesis \| Prostaglandin Receptor
Molecular Weight	310.27
Appearance	Solid
Synonyms	HR325
SMILES	O=C(NC1=CC=C(C(F)(F)F)C(C)=C1)/C(C#N)=C(C2CC2)\O
Purity	99.76%

Storage & Handling

Shipping	Room temperature in continental US. May vary elsewhere.
Storage	Powder: -20°C/3 years; 4°C/2 years In solvent: -80°C/6 months; -20°C/1 month
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.

! For research use only, not intended for any clinical use.